ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $3 | -70.0% | 2,307 | -76.5% | 0.00% | – |
| Q4 2023 | $10 | -86.1% | 9,798 | -6.5% | 0.00% | -100.0% |
| Q3 2023 | $72 | -33.9% | 10,484 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $109 | +47.3% | 10,484 | +15.2% | 0.00% | 0.0% |
| Q1 2023 | $74 | -55.2% | 9,098 | -13.0% | 0.00% | 0.0% |
| Q4 2022 | $165 | -99.9% | 10,453 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $165,000 | +25.0% | 10,453 | +10.6% | 0.00% | +100.0% |
| Q2 2022 | $132,000 | -7.7% | 9,452 | +13.8% | 0.00% | 0.0% |
| Q1 2022 | $143,000 | – | 8,306 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
| Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
| GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
| Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
| VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
| Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
| Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
| BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |